Britannia Pharmaceuticals simplifies apomorphine delivery with new Pre-Filled Syringe

Main Category: Parkinson's Disease
Article Date: 11 Jan 2005 - 12:00 PDT

email to a friend   printer friendly   opinions  

Britannia Pharmaceuticals announces today the availability of the APO-go Pre-Filled Syringe (PFS), an easier to use presentation for Parkinson's disease patients using apomorphine by continuous infusion with an APO-go pump.

Patients requiring a continuous subcutaneous infusion of apomorphine use an APO-go pump to administer their drug. The new APO-go PFS contains a 5mg/ml concentration of apomorphine hydrochloride which is ready for transfer to a plastic syringe specifically designed for use with an APO-go pump. There is no longer a need to break ampoules thereby reducing the time of the preparation procedure.

The advantages to the new APO-go PFS include:

-- Quick and simple
-- Pre-dilution ensures accurate dosage
-- Reduced likelihood of spillage or contamination
-- No need to break ampoules thereby eliminating associated risks
-- Lower cost to NHS compared with separate APO-go and saline ampoules

James Carter, Marketing Manager for Britannia Pharmaceuticals commented, "The APO-go pump has been a major benefit to patients who require apomorphine infusions, being small, discreet and relatively easy to use. With our new APO-go PFS the time to prepare an infusion has been further reduced and its use eliminates the risk of injury that was possible when using glass ampoules and needles. Finally, being pre-diluted and ready for a quick and simple transfer, APO-go PFS represents good pharmaceutical practice."

An image to accompany this release is available for download if you CLICK HERE

-ends-

About Britannia Pharmaceuticals

Founded in 1981, Britannia Pharmaceuticals Limited is a United Kingdom-based pharmaceutical firm whose mission is to become a leading supplier of innovative products for niche medical conditions. The company has pioneered new treatments for some of the world's most debilitating conditions including asthma, Parkinson's disease, drug addiction, and migraine. In addition to these treatments, Britannia has also developed nasal and respiratory drug delivery technologies that are applicable to a range of treatments. Britannia is a Forum Bioscience company. Visit Britannia's website at http://www.britannia-pharm.co.uk.

Contacts:
James Carter
James.carter@forumgroup.co.uk
+44 (0) 1737 857759

Sue Glanville
sglanville@europrgroup.com
+44 (0) 20 8917 4923

• Additional
• References
• Citations